Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033992 · ClinicalTrials.gov registry record · NA
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
A NA study of Malignant Glioma and Diffuse Intrinsic Pontine Glioma, sponsored by Children's Oncology Group.
- Active
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 11
- Study locations
NCT03033992: Active NA study of Malignant Glioma and Diffuse Intrinsic Pontine Glioma, sponsored by Children's Oncology Group.
NCT03033992 is a NA study of Malignant Glioma and Diffuse Intrinsic Pontine Glioma that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 80 participants, below the 90-participant average among 40 other Malignant Glioma trials with a reported enrollment target (11% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03033992, a NA study of Malignant Glioma and Diffuse Intrinsic Pontine Glioma, is active but no longer recruiting, sponsored by Children's Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a multicenter trial of the Optune device to examine the feasibility and to describe the device-related toxicity in children with supratentorial high grade glioma (HGG) or ependymoma (Stratum 1) and to examine the feasibility and efficacy of concurrent Optune and standard focal radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) (Stratum 2).
Primary Outcome
Stratum 1: Device Usage Compliance will be reported to assess the feasibility of the device treatment.
Conditions Studied
Interventions
- DEVICE Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)
- COMBINATION_PRODUCT Concurrent Optune and RT followed by Optune System alone
Study Locations (11)
California
- Children's Hospital Los Angeles - Los Angeles
- Lucile Packard Children's Hospital at Stanford University Medical Center - Palo Alto
Arizona
- Phoenix Children's Hospital - Phoenix
Colorado
- Children's Hospital of Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Atlanta
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-04-04 |
| Est. Completion | 2031-07-21 |
| Phase | NA |
What the registry record for NCT03033992 still lists
NCT03033992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 90-participant average among 40 other Malignant Glioma trials with a reported enrollment target (11% lower).
The record links to 3 conditions, with Malignant Glioma appearing as the primary indexed condition, and to 2 interventions - of which Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields) is the first listed.
NCT03033992 lists 11 locations in 10 states (California, Arizona, Colorado).
Frequently Asked Questions
What is clinical trial NCT03033992 about?
NCT03033992 is a clinical study titled "Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG". This is a multicenter trial of the Optune device to examine the feasibility and to describe the device-related toxicity in children with supratentorial high grade glioma (HGG) or ependymoma (Stratum 1) and to examine the feasibility and efficacy of concurrent Optune and standard focal radiation ther...
What is the current status of trial NCT03033992?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2017-04-04. Estimated completion is 2031-07-21.
What conditions does trial NCT03033992 study?
This clinical trial studies the following conditions: Malignant Glioma, Diffuse Intrinsic Pontine Glioma, Ependymoma.
What interventions are being tested in trial NCT03033992?
The interventions under investigation include: Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields) (DEVICE), Concurrent Optune and RT followed by Optune System alone (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03033992?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03033992 being conducted?
This trial has 11 study locations across Arizona, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03033992's enrollment target sits among peer trials
80 10th of 40 higher than 30 of 40 other Malignant Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fitness and Nutrition in Glioma
RECRUITING · NA
-
Non-invasive Glioma Characterization Through Molecular Imaging
RECRUITING · NA
-
T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas
RECRUITING · NA
-
Mind-Body Intervention in Glioma Couples
ACTIVE NOT RECRUITING · NA
-
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
COMPLETED · NA
-
Mapping of Electrical Properties in the Brain
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI